There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), Alkermes (ALKS – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with bullish sentiments.
Atricure (ATRC)
In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Atricure, with a price target of $65.00. The company’s shares closed last Friday at $23.17, close to its 52-week low of $22.07.
According to TipRanks.com, O’Brien is a 4-star analyst with an average return of
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $51.89, a 128.6% upside from current levels. In a report issued on April 23, Oppenheimer also upgraded the stock to Buy with a $32.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Alkermes (ALKS)
Piper Sandler analyst David Amsellem maintained a Buy rating on Alkermes today and set a price target of $39.00. The company’s shares closed last Friday at $24.68.
According to TipRanks.com, Amsellem has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $35.50 average price target, which is a 44.6% upside from current levels. In a report issued on April 16, Mizuho Securities also maintained a Buy rating on the stock with a $35.00 price target.
Bristol-Myers Squibb (BMY)
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Bristol-Myers Squibb today and set a price target of $56.00. The company’s shares closed last Friday at $44.85, close to its 52-week low of $44.34.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
Bristol-Myers Squibb has an analyst consensus of Hold, with a price target consensus of $53.53, implying a 19.8% upside from current levels. In a report issued on April 26, Truist Financial also maintained a Buy rating on the stock with a $64.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRC:
